Cima Linda G

Bio: Cima Linda G is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Selective laser sintering. The author has an hindex of 1, co-authored 1 publications receiving 472 citations.

Preparation of medical devices by solid free-form fabrication methods

Abstract: Solid free-form techniques for making medical devices for controlled release of bioactive agent and implantation and growth of cells are described using computer aided design. Examples of SFF methods include stereo-lithography (SLA), selective laser sintering (SLS), ballistic particle manufacturing (BPM), fusion deposition modeling (FDM), and three dimensional printing (3DP). The macrostructure and porosity of the device can be manipulated by controlling printing parameters. Most importantly, these features can be designed and tailored using computer assisted design (CAD) for individual patients to optimize therapy.

The design of scaffolds for use in tissue engineering. Part II. Rapid prototyping techniques

Abstract: Tissue engineering (TE) is an important emerging area in biomedical engineering for creating biological alternatives for harvested tissues, implants, and prostheses. In TE, a highly porous artificial extracellular matrix or scaffold is required to accommodate mammalian cells and guide their growth and tissue regeneration in three-dimension (3D). However, existing 3D scaffolds for TE proved less than ideal for actual applications because they lack mechanical strength, interconnected channels, and controlled porosity or pores distribution. In this paper, the authors review the application and advancement of rapid prototyping (RP) techniques in the design and creation of synthetic scaffolds for use in TE. We also review the advantages and benefits, and limitations and shortcomings of current RP techniques as well as the future direction of RP development in TE scaffold fabrication.

The Design of Scaffolds for Use in Tissue Engineering

Abstract: Problems: Tissue engineering (TE) is one of the modern strategies to provide a functional biological tissue equivalent to restore or improve the function of human tissues that lost by disease, traumatic events, or congenital abnormalities. Some essential factors in TE are tissue type and appropriate scaffold. suitable influence on cell viability and proliferation is One of the most important characteristics of a appropriate scaffold for tissue engineering. The purpose of this research was to comparative evaluation of adipose derived stem cells (ADSCs) proliferation rate and their viability on the five different scaffolds. Experimental approach: six different scaffolds were prepared including Alginate, Poly Lactic Glycolic Acid (PLGA), Fibrin glue (FG), Inactive Platelet- Rich Plasma (IPRP), Active Platelet- Rich Plasma (APRP) and Hydroxyapatite/ β

Delivery system attachment

Abstract: A covering for delivering a substance or material to a surgical site is provided. The covering, with substance provided therein, may be referred to as a delivery system. Generally, the covering may be a single or multi-compartment structure capable of at least partially retaining a substance provided therein until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the substance or surrounding materials. For example, the substance may be released (actively or passively) to the surgical site. The covering may participate in, control, or otherwise adjust, the release of the substance.

Minimally Invasive Medical Implant Devices for Controlled Drug Delivery

Abstract: Implantable medical devices and methods of use are provided for controlled drug delivery. The devices may include an elongated body dimensioned to facilitate minimally invasive and complete implantation into a patient, wherein the elongated body portion comprises a first, closed end portion, a second closed end portion and an intermediate portion disposed between and connected to the first closed end portion and the second closed end portion; two or more discrete reservoirs disposed in the elongated body portion, each reservoir having one or more openings; a drug formulation, which comprises at least one drug, disposed in the two more discrete reservoirs; and reservoir caps closing off the one or more openings of each reservoir, wherein release of the drug in vivo is controlled at least in part by the in vivo disintegration or permeabilization of the discrete reservoir caps.